Augustin Amour

List of Publications by Year
in descending order

35 papers	2,567 citations	331670 21 h-index	377865 34 g-index
36 all docs	36 docs citations	36 times ranked	2957 citing authors

#	Article	IF	Citations
1	TNF-Î± converting enzyme (TACE) is inhibited by TIMP-3. FEBS Letters, 1998, 435, 39-44.	2.8	547
2	The in vitro activity of ADAMâ€10 is inhibited by TIMPâ€1 and TIMPâ€3. FEBS Letters, 2000, 473, 275-279.	2.8	351
3	Membrane Type 4 Matrix Metalloproteinase (MMP17) Has Tumor Necrosis Factor-Î± Convertase Activity but Does Not Activate Pro-MMP2. Journal of Biological Chemistry, 2000, 275, 14046-14055.	3.4	195
4	Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's Î²-secretase. Journal of Cell Biology, 2003, 163, 97-107.	5.2	175
5	The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Letters, 2002, 524, 154-158.	2.8	128
6	Acute Respiratory Distress Syndrome Neutrophils Have a Distinct Phenotype and Are Resistant to Phosphoinositide 3-Kinase Inhibition. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 961-973.	5.6	125
7	Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase Î´ for the Treatment of Respiratory Disease. Journal of Medicinal Chemistry, 2015, 58, 7381-7399.	6.4	118
8	Localization of the Death Domain of Tissue Inhibitor of Metalloproteinase-3 to the N Terminus. Journal of Biological Chemistry, 2000, 275, 41358-41363.	3.4	112
9	ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. International Journal of Cancer, 2006, 118, 263-273.	5.1	84
10	Enzyme Accessibility and Solid Supports: Which Molecular Weight Enzymes Can Be Used on Solid Supports? An Investigation Using Confocal Raman Microscopy. Chemistry - A European Journal, 2002, 8, 3769.	3.3	73
11	TIMP-3 Inhibition of ADAMTS-4 (Aggrecanase-1) Is Modulated by Interactions between Aggrecan and the C-terminal Domain of ADAMTS-4. Journal of Biological Chemistry, 2007, 282, 20991-20998.	3.4	63
12	Targeting phosphoinositide 3â€kinase Î´ for the treatment of respiratory diseases. Annals of the New York Academy of Sciences, 2013, 1280, 35-39.	3.8	60
13	Discovery of Further Pyrrolidinetrans-Lactams as Inhibitors of Human Neutrophil Elastase (HNE) with Potential as Development Candidates and the Crystal Structure of HNE Complexed with an Inhibitor (GW475151). Journal of Medicinal Chemistry, 2002, 45, 3878-3890.	6.4	53
14	The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastaseâ€"GW311616A a development candidate. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 895-898.	2.2	52
15	Study of bradykinin metabolism in human and rat plasma by liquid chromatography with inductively coupled plasma mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry. Rapid Communications in Mass Spectrometry, 2002, 16, 220-228.	1.5	50
16	A broad-spectrum fluorescence-based peptide library for the rapid identification of protease substrates. Proteomics, 2006, 6, 2112-2120.	2.2	45
17	Design and Synthesis of Hydrazinopeptides and Their Evaluation as Human Leukocyte Elastase Inhibitors. Journal of Medicinal Chemistry, 1998, 41, 4833-4843.	6.4	43
18	Targeting phosphoinositide 3-kinase Î´ for allergic asthma. Biochemical Society Transactions, 2012, 40, 240-245.	3.4	42

#	Article	IF	Citations
19	The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3. FEBS Letters, 2002, 520, 102-106.	2.8	33
20	Synthesis and evaluation of Î´-Lactams (Piperazones) as elastase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 387-389.	2.2	30
21	Continuous real-time measurement of tumor necrosis factor-Î± converting enzyme activity on live cells. Laboratory Investigation, 2005, 85, 1440-1448.	3.7	24
22	Evolution of a Novel, Orally Bioavailable Series of PI3KÎ´ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease. Journal of Medicinal Chemistry, 2016, 59, 7239-7251.	6.4	22
23	Organ-on-chip applications in drug discovery: an end user perspective. Biochemical Society Transactions, 2021, 49, 1881-1890.	3.4	22
24	Stereoselective synthesis and inhibitor properties towards human leucocyte elastase of chiral Î²-peptidyl trifluoromethyl alcohols.. Tetrahedron: Asymmetry, 1994, 5, 1099-1110.	1.8	21
25	Organ-on-a-chip: current gaps and future directions. Biochemical Society Transactions, 2022, 50, 665-673.	3.4	17
26	Synthesis and proteaseâ€catalyzed hydrolysis of a novel hydrazinopeptide. International Journal of Peptide and Protein Research, 1994, 43, 297-304.	0.1	16
27	Inhibition of the Metalloproteinase Domain of Mouse TACE. Annals of the New York Academy of Sciences, 1999, 878, 728-731.	3.8	13
28	Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates. Analytical Biochemistry, 2009, 384, 56-67.	2.4	13
29	Exploring PI3KÎ´ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials. International Journal of COPD, 2021, Volume 16, 1621-1636.	2.3	13
30	Converging TLR9 and PI3Kgamma signaling induces sterile inflammation and organ damage. Scientific Reports, 2019, 9, 19085.	3.3	10
31	An investigation of the antiâ€inflammatory effects and a potential biomarker of <scp>PI</scp>3KÎ´ inhibition in <scp>COPD</scp> T cells. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 932-940.	1.9	9
32	The 5-Phosphatase SHIP2 Promotes Neutrophil Chemotaxis and Recruitment. Frontiers in Immunology, 2021, 12, 671756.	4.8	4
33	Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3KÎ´ with a Novel Binding Mode. Journal of Medicinal Chemistry, 2021, 64, 13780-13792.	6.4	3
34	Functional capacity of alveolar neutrophils in acute respiratory distress syndrome. Lancet, The, 2014, 383, S64.	13.7	1
35	Heparan sulphate binds the aspartic protease Î²-Secretase and regulates cleavage of APP. Biochemical Society Transactions, 2002, 30, A69-A69.	3.4	0